Resistance Profiles of Cyclic and Linear Inhibitors of HIV-1 Protease

Resistance to anti-HIV protease drugs is a major problem in the design of AIDS drugs with long-term efficacy. To identify structural features associated with a certain resistance profile, the inhibitory properties of a series of symmetric and asymmetric cyclic sulfamide, cyclic urea and linear transition-state analogue inhibitors of HIV-1 protease were investigated using wild-type and mutant enzyme. To allow a detailed structure-inhibition analysis, enzyme with single, double, triple and quadruple combinations of G48V, V82A, I84V and L90M substitutions was used. Kinetic analysis of the mutants revealed that catalytic efficiency was 1–30% of that for the wild-type enzyme, a consequence of reduced kcat in all cases and an increased KM for all mutants except for the G48V enzyme. The overall structure-inhibitory profiles of the cyclic compounds were similar, and the inhibition of the V82A, I84V and G48V/L90M mutants were less efficient than of the wild-type enzyme. The greatest increase in Ki was generally observed for the I84V mutant and least for the G48V/L90M mutant, and additional combinations of mutations did not result in improved inhibition profiles for the cyclic compounds. An extended analysis of additional mutants, and including a set of linear compounds, showed that the profile was unique for each compound, and did not reveal any general structural features associated with a certain inhibition profile. The effects of structural modifications in the inhibitors, or of mutations, were not additive and they differed depending on their context. The results demonstrate the difficulties in predicting resistance, even for closely related compounds, and designing compounds with improved resistance profiles.

[1]  J. Louis,et al.  Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. , 2000, European journal of biochemistry.

[2]  J. Hulten,et al.  Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors. , 2001, Journal of medicinal chemistry.

[3]  Chang,et al.  Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors , 1998, Chemistry & biology.

[4]  T. Merigan,et al.  Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. , 1999, AIDS.

[5]  J. Hulten,et al.  Inhibitors of the C(2)-symmetric HIV-1 protease: nonsymmetric binding of a symmetric cyclic sulfamide with ketoxime groups in the P2/P2' side chains. , 1999, Journal of medicinal chemistry.

[6]  P. Lam,et al.  Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors. , 1997, Biochemistry.

[7]  M. Hämäläinen,et al.  Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology. , 2001, Analytical biochemistry.

[8]  S. Gulnik,et al.  Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. , 1995, Biochemistry.

[9]  L. Vrang,et al.  Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitors. , 1999, Journal of medicinal chemistry.

[10]  A Wlodawer,et al.  Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate. , 1998, Biochemistry.

[11]  R. Myers,et al.  In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease , 1995, Journal of virology.

[12]  A. Tomasselli,et al.  Targeting the HIV-protease in AIDS therapy: a current clinical perspective. , 2000, Biochimica et biophysica acta.

[13]  S Foundling,et al.  Structure of a G48H mutant of HIV‐1 protease explains how glycine‐48 replacements produce mutants resistant to inhibitor drugs 1 , 1997, FEBS letters.

[14]  Chong-Hwan Chang,et al.  Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas. , 1996, Journal of medicinal chemistry.

[15]  J. Åqvist,et al.  Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities. , 1997, Journal of medicinal chemistry.

[16]  PatrickY.-S. Lam,et al.  Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. , 1994, Science.

[17]  H. B. Schock,et al.  Non-active Site Changes Elicit Broad-based Cross-resistance of the HIV-1 Protease to Inhibitors* , 1999, The Journal of Biological Chemistry.

[18]  J. Hulten,et al.  Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs , 1997, Antimicrobial agents and chemotherapy.

[19]  J. Mellors,et al.  3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine , 2000, Annals of Internal Medicine.

[20]  Miguel Ángel Martínez,et al.  Emergence and genetic evolution of HIV‐1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors , 1999, Journal of medical virology.

[21]  M. Lindgren,et al.  Investigation of an allosteric site of HIV-1 proteinase involved in inhibition by Cu2+. , 1998, Advances in experimental medicine and biology.

[22]  J. Fantini,et al.  Comparison of Human Immunodeficiency Virus Type 1 (HIV-1) Protease Mutations in HIV-1 Genomes Detected in Plasma and in Peripheral Blood Mononuclear Cells from Patients Receiving Combination Drug Therapy , 1999, Journal of Clinical Microbiology.

[23]  K Osterlund,et al.  Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor. , 1997, Journal of medicinal chemistry.

[24]  J L Meek,et al.  Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. , 1996, Chemistry & biology.

[25]  A Wlodawer,et al.  Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. , 1998, Annual review of biophysics and biomolecular structure.

[26]  C. Petropoulos,et al.  Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. , 2000, The Journal of infectious diseases.

[27]  M. Ott,et al.  In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. , 1996, The Journal of infectious diseases.

[28]  I. Duncan,et al.  HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy , 1998, AIDS.

[29]  John L. Sullivan,et al.  Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy , 2000, Nature Medicine.

[30]  I B Duncan,et al.  Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. , 1995, Virology.

[31]  B. Samuelsson,et al.  Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold. , 1998, Journal of medicinal chemistry.

[32]  P. Jadhav,et al.  Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. , 1997, Journal of medicinal chemistry.

[33]  Douglas D. Richman,et al.  HIV chemotherapy , 2001, Nature.

[34]  M. Otto,et al.  Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors. , 1995, Antiviral research.

[35]  D. R. Kuritzkes,et al.  Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir , 1998, Antimicrobial Agents and Chemotherapy.

[36]  D. Lamarre,et al.  Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors , 1996, Journal of virology.